Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

UFS responds to revocation of the accreditation of the SA Doping Control Laboratory by WADA
2017-07-01

The World Anti-Doping Agency (WADA) yesterday informed the South African Doping Control Laboratory (SADoCoL) at the University of the Free State (UFS) that the WADA accreditation status of the laboratory has been revoked.

This revocation does, however, not include the analysis of blood samples for the Athlete Biological Passport for which SADoCoL has been re-accredited in August 2016 and which the laboratory will continue to perform. It also does not impact at all on the testing of urine sport samples by the South African Institute of Drug-free Sport (SAIDS), who will continue to send such samples for testing to other WADA accredited laboratories, while blood samples will be tested at SADoCoL as before.

The revocation follows a year long period of suspension in which the laboratory had to develop its analytical capabilities and instate new systems and methodologies.  “In this period the laboratory worked diligently to realize all of these requirements and according to an inspection team from the WADA Laboratory Expert Group who visited the laboratory in February 2017, much has been done and the Laboratory is in a much better state than it was before the suspension in May 2016,” says prof Marthinus van der Merwe, Director of SADoCoL.

“However, there were certain aspects of these requirements that the laboratory could not achieve within the time-frame stipulated by WADA and therefore the organisation is bound by its rules and regulations to now revoke the accreditation status of the laboratory. Since much effort and resources have been invested in the laboratory in the last two years, the management of SADoCoL together with senior leadership of the UFS decided to go ahead and finalise all development in order to re-apply for WADA accreditation,” says prof van der Merwe. 

“The UFS fully acknowledges the hard work of SADoCoL during the period of development and is committed to support the laboratory in its endeavors to re-attain its status within the very specialised and highly regulated community of world-wide doping control laboratories.  The premium goal of the laboratory is still to fully serve the sporting community of South Africa and Africa according to the WADA guidelines for anti-doping control in Sport and it is confident to attain that with the support of all role players in this field,” says Prof Witthuhn, Vice-Rector: Research at the UFS.

Released by:
Lacea Loader (Director: Communication and Brand Management)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za
Fax: +27 51 444 6393

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept